Achaogen (AKAO) is an infectious disease company developing small molecules to treat infection caused by multi-drug resistant bacterial infections. IPO in March 2014.
Alexza (ALXA) is a drug delivery company that develops drugs for delivery locally and systemically through the lungs. IPO in March 2006.
Ambrx is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Acquired in June 2015.
Arvinas is translating innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases.
Atterocor is developing a small-molecule adrenal targeting therapeutic for adrenocortical carcinoma (ACC) and Cushing’s syndrome.
Audentes is development innovative treatments for people with serious, rare muscle diseases through adeno-associated virus (AAV) gene therapy.
Bellerophon (BLPH) is developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. IPO in February 2015.
Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules.
Biotie (BTH1V) is a biopharmaceutical company developing and commercializing products for neurodegenerative and psychiatric disorders. Acquired Synosia, a 5AM company, February 2011.
Calibrium is a biopharmaceutical company developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Acquired by Novo Nordisk (NVO) in August 2015.
Cellular Research is a life science research tools company developing tools for single-cell genetic analysis based on its proprietary molecular indexing technology. Acquired by Becton Dickinson (BDX) in August 2015.
Ceterix is a medical device company commercializing minimally invasive surgical tools within the arthroscopy market.
Chrono Therapeutics (CHRONO) is a pharmaceutical company founded in 2004 with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support.
Cidara Therapeutics (CDTX) is applying its small molecule immunotherapy platform to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. IPO in April 2015.
Cleave is developing small molecule therapeutics active in protein homeostasis pathways for treating cancer.
DVS is commercializing mass cytometry instruments and reagents to characterize individual cells based on surface proteins, with various research and clinical applications. Acquired by Fluidigm (FLDM) in February 2014.
EntreMed (ENMD) is a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer and inflammatory disease. Acquired Miikana, a 5AM company, in January 2006.
Envoy discovered novel drug targets and pharmaceuticals using platform technology for cell-specific gene expression profiling with a therapeutic focus on central nervous system and metabolic disease indications. Acquired by Takeda (TKPHF) in November 2012.
Epirus (EPRS) is developing a broad portfolio of biosimilar monoclonal antibodies and therapeutic proteins, focused in immunology and oncology. Merged into public company in 2014.
Flexion (FLXN) is a clinical-stage pharmaceutical company developing therapeutics for the treatment of musculoskeletal diseases and pain. IPO in February 2014.
Igenica is a biopharmaceutical company discovering and developing antibody therapeutics for the treatment of cancer.
Ikaria, formed from a combination of Ikaria and INO Therapeutics, is a commercial stage critical care therapeutics company in therapeutic gases. Acquired by Madison Dearborn Partners in February 2014.
Ilypsa was a biopharmaceutical company developing non-absorbed pharmaceuticals for renal and metabolic diseases. Acquired by Amgen (AMGN) July 2007.
Incline was a hospital focused specialty pharmaceutical company developing a transdermal iontophoretic patch for patient controlled analgesia following surgery. Acquired by The Medicines Company (MDCO) in January 2013.
KaloBios (KBIO) is a biopharmaceutical company developing human antibody therapeutics for oncology and respiratory diseases. IPO in January 2013.
Kinestral is developing adaptive, dynamic glass for commercial, residential and automotive markets.
Marcadia was a biopharmaceutical company developing therapeutics for the treatment of diabetes and obesity. Acquired by Roche (RHHBY) in December 2010.
Novira is an antiviral drug discovery company that is focused on the development of first-in-class antiviral therapeutics for the treatment of serious diseases including chronic hepatitis B.
Panomics was a research instrument and reagents company which developed cell-based assays and instruments for quantitative multiplexed measurements of molecular events. Acquired by Affymetrix (AFFX) in December 2008.
Pear Therapeutics combines digital therapies with supplements, medical foods, and pharmaceuticals to create more effective treatment solutions.
Pearl was a biopharmaceutical company developing inhalable formulations for the treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD). Acquired by AstraZeneca (AZN) in June 2013.
PhaseRx is an RNAi delivery company developing polymer-based approaches for systemic delivery of RNAi drugs.
Pulmatrix (PULM) is a clinical stage company with a unique inhaled dry powder platform advancing a pipeline of respiratory disease therapies. Merged into public company in June 2015.
Relypsa (RLYP) is a clinical-stage biopharmaceutical company developing non-absorbed polymeric drugs, including a potassium-binding agent for hyperkalemia associated with cardiovascular and renal disease. IPO in November 2013.
Rennovia is developing chemocatalytic processes for converting biorenewable feedstocks into high value and commodity chemicals.
RuiYi is discovering and developing biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs).
scPharmaceuticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.
Semprus was a medical device company developing permanent antimicrobial & anti-biofouling surfaces for use on indwelling devices. Acquired by Teleflex (TFX) in May 2012.
Spyryx Biosciences is developing next generation therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and COPD.
Startide Sciences is a 5AM Ventures portfolio company based in the San Francisco area chartered to identify groundbreaking life science companies that can benefit from active capital.
VBI (VBIV) is an infectious disease company developing vaccines against Cytomegalovirus and other pathogens. Merged into public company in July 2014.
Viveve (VIVMF) is commercializing a non-surgical, non-ablative medical device for use in women’s health. Merged into public company in September 2014.
Wildcat is a high-throughput materials research company developing advanced battery materials for consumer and industrial applications.